


This listing of claims will replace all prior versions, and listings, of claims in the application:

In The Claims:

1-28. (Canceled)

29. (Original) A method of treating renal osteodystrophy comprising administering to a patient with renal osteodystrophy an effective amount of (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol having the formula:



30. (Original) The method of claim 29 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered orally.

31. (Original) The method of claim 29 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered parenterally.

32. (Original) The method of claim 29 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered transdermally.

33. (Original) The method of claim 29 wherein (20S)-1 α -hydroxy-2-methylene-19-nor-bishomopregnacalciferol is administered in a dosage of from about 0.01 μ g/day to about 100 μ g/day.